Cargando…

Corrigendum to: Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis

Detalles Bibliográficos
Autores principales:	Schäfer, Martin, Meißner, Yvette, Kekow, Jörn, Berger, Sylvia, Remstedt, Sven, Manger, Bernhard, Listing, Joachim, Strangfeld, Anja, Zink, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382592/ https://www.ncbi.nlm.nih.gov/pubmed/32073630 http://dx.doi.org/10.1093/rheumatology/keaa049

Ejemplares similares

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
por: Meissner, Yvette, et al.
Publicado: (2016)

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
por: Baganz, Lisa, et al.
Publicado: (2017)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT
por: Schäfer, Martin, et al.
Publicado: (2020)

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort
por: Meissner, Y, et al.
Publicado: (2017)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
por: Listing, Joachim, et al.
Publicado: (2006)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT
por: Gerhold, Kerstin, et al.
Publicado: (2015)

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
por: Strangfeld, Anja, et al.
Publicado: (2010)

Evaluation of the RABBIT Risk Score for serious infections
por: Zink, A, et al.
Publicado: (2014)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register
por: Richter, Adrian, et al.
Publicado: (2014)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Corrigendum to “Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma”
por: Macià, A., et al.
Publicado: (2016)

Corrigendum: Targeting prion-like protein spreading in neurodegenerative diseases
Publicado: (2018)

Corrigendum to “Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer”
por: Marrugal, Ángela, et al.
Publicado: (2018)

Corrigendum to: 204. Mucosal Cytokine Profiles in Children with COVID-19
por: Quintero, Ana M, et al.
Publicado: (2022)

Neues aus dem RABBIT-Register
por: Meißner, Yvette, et al.
Publicado: (2021)

Corrigendum to “An Insight into Methods and Practices in Hip Arthroplasty in Patients with Rheumatoid Arthritis”
por: Mosleh-shirazi, Mohammad Saeed, et al.
Publicado: (2016)

Corrigendum to “An Efficient CNN for Hand X-Ray Classification of Rheumatoid Arthritis”
por: Mate, Gitanjali S., et al.
Publicado: (2021)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Publicado: (2019)

Corrigendum: Targeting a portion of central European spider diversity for permanent preservation
por: Čandek, Klemen, et al.
Publicado: (2015)

Current management strategies to target the increasing incidence of diabetes within Pakistan [Corrigendum]
Publicado: (2019)

Sarcopenia May Be a Risk Factor for Osteoporosis in Chinese Patients with Rheumatoid Arthritis [Corrigendum]
Publicado: (2022)

Upregulated LINC00565 Accelerates Ovarian Cancer Progression by Targeting GAS6 [Corrigendum]
Publicado: (2020)

Corrigendum: Target inhibition of caspase-8 alleviates brain damage after subarachnoid hemorrhage
Publicado: (2020)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Corrigendum: Tumour‐associated macrophages as a novel target of VEGI‐251 in cancer therapy
Publicado: (2022)

Folate Decorated Multifunctional Biodegradable Nanoparticles for Gastric Carcinoma Active Targeting Theranostics [Corrigendum]
Publicado: (2022)

Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer [Corrigendum]
Publicado: (2023)

Corrigendum: Comparative Analysis of Human Epidermal and Peripheral Blood γδ T Cell Cytokine Profiles
por: Kim, Kwangmi, et al.
Publicado: (2014)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Publicado: (2013)

Corrigendum to “Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury”
por: Ji, Hongming, et al.
Publicado: (2018)

Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex [Corrigendum]
Publicado: (2019)

Corrigendum to “Targeting HIF-1α to Prevent Renal Ischemia-Reperfusion Injury: Does It Work?”
por: Sethi, Kapil, et al.
Publicado: (2019)

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]
Publicado: (2021)

Solid Lipid Nanoparticles for Thermoresponsive Targeting: Evidence from Spectrophotometry, Electrochemical, and Cytotoxicity Studies [Corrigendum]
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqucget2ram8pc96il8r3f58ug